Metsera (MTSR) Competitors

Metsera (NASDAQ:MTSR) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Is MTSR or GMAB more profitable?

Genmab A/S has a net margin of 35.11% compared to Metsera's net margin of 0.00%. Genmab A/S's return on equity of 18.08% beat Metsera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metsera	N/A	N/A	N/A
Genmab A/S	35.11%	18.08%	14.52%

Which has stronger valuation & earnings, MTSR or GMAB?

Genmab A/S has higher revenue and earnings than Metsera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metsera	N/A	N/A	-$209.13M	N/A	N/A
Genmab A/S	$3.12B	4.82	$1.14B	$1.76	13.30

Do analysts recommend MTSR or GMAB?

Metsera currently has a consensus target price of $55.00, suggesting a potential upside of 35.90%. Genmab A/S has a consensus target price of $37.80, suggesting a potential upside of 61.54%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Metsera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metsera	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Do institutionals and insiders hold more shares of MTSR or GMAB?

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the media prefer MTSR or GMAB?

In the previous week, Metsera had 3 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Metsera and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.27 beat Metsera's score of 0.93 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metsera	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Metsera on 11 of the 13 factors compared between the two stocks.